Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B2065 in Acute Ischemic Stroke
NCT07371624Phase 2Recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of B2065 in ischemic stroke, sponsored by Tasly Pharmaceutical Group Co., Ltd.. Started Dec 2025; status: recruiting.
02
Drugs
B2065
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07371624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371624.